SCHEMBL19975062

SCHEMBL19975062

CC(C(O)C(=O)NCC1CC1)N(C=O)c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 1/20 0.46
PTGIR P43119 1/20 0.45
FBP1 P09467 1/20 0.42
F10 P00742 4/20 0.41
PRSS1 P07477 4/20 0.41
EPHX1 P07099 1/20 0.41
EPHX2 P34913 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
ADAM17 P78536 1/20 0.39
CNR2 P34972 1/20 0.38
KCNH2 Q12809 1/20 0.37
CACNA1I Q9P0X4 1/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974695 0.88 PTGIR (0.47) ALDH1A1GAAL3MBTL1PTGIRF10
SCHEMBL19974938 0.86 SMN1; SMN2 (0.47) ALDH1A1GAAL3MBTL1POLBPTGIR
SCHEMBL19975274 0.86 PTGIR (0.41) ALDH1A1GAAPTGIRF10PRSS1
SCHEMBL28316683 0.85 F10 (0.41) ALDH1A1GAAL3MBTL1F10PRSS1
SCHEMBL19975567 0.83 ALDH1A1 (0.46) ALDH1A1GAAL3MBTL1POLBPTGIR
SCHEMBL19974728 0.82 BCHE (0.42) ALDH1A1GAAL3MBTL1PTGIREPHX1
SCHEMBL19975353 0.82 BCHE (0.45) ALDH1A1GAAL3MBTL1EPHX1EPHX2
SCHEMBL19974925 0.81 MEN1 (0.39) ALDH1A1GAAL3MBTL1PTGIRF10
SCHEMBL21176166 0.81 BCHE (0.46) ALDH1A1GAAL3MBTL1EPHX1EPHX2
SCHEMBL19975143 0.81 PTGIR (0.43) ALDH1A1GAAL3MBTL1PTGIRF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C ALDH1A1 2271/4885GAA 75/4885L3MBTL1 1238/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C ALDH1A1 2673/4885GAA 107/4885L3MBTL1 1885/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C ALDH1A1 2271/4885GAA 75/4885L3MBTL1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.